Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients
Open Access
- 12 July 2014
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 89 (10) , E176-E183
Abstract
Among cancers treated with allogeneic hematopoietic stem‐cell transplantation (HSCT), some are sensitive to natural killer (NK) cell reactivity, described as the “missing self” recognition effect. However, this model disregarded the NK cell licensing effect, which highly increases the NK cell reactivity against tumor and is dependent on the coexpression of inhibitory killer cell immunoglobulin‐like receptor (iKIR) and its corresponding HLA Class I ligand. We assessed clinical data, HLA and donor iKIR genotyping in 283 patients with myelo‐ and lymphoproliferative malignancies who underwent HSCT from unrelated donors. We found dramatically reduced overall survival (OS), progression free survival (PFS), and time to progression (TTP) among patients with malignant diseases with the lack of HLA ligand cognate with this iKIR involved in NK cell licensing in corresponding donor (events 83.3% vs. 39.8%, P = 0.0010; 91.6% vs. 47.7%, P = 0.00010; and 30.0% vs. 17.3%, P = 0.013, for OS, PFS, and TTP, respectively). The extremely adverse PFS have withstand the correction when patient group was restricted to HLA mismatched donor‐recipient pairs. The incidence of aGvHD was comparable in two groups of patients. In malignant patients after HSCT the missing HLA ligand for iKIR involved in NK cell licensing in corresponding donor (“missing licensing proof”) induced extremely adverse survival of the patients due to the progression of malignancy and not to the aGvHD. Avoiding the selection of HSCT donors with the “missing licensing proof” in the malignant patient is strongly advisable.Am. J. Hematol. 89:E176–E183, 2014.Keywords
Funding Information
- National Centre for Research and Development, Poland (N R13 0082 06)
This publication has 29 references indexed in Scilit:
- Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.Blood, 2007
- Killer cell Ig‐like receptors ligand‐mismatched, alloreactive natural killer cells lyse primary solid tumorsCancer, 2006
- Licensing of natural killer cells by host major histocompatibility complex class I moleculesNature, 2005
- Analysis of the receptor-ligand interactions in the natural killer–mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)Blood, 2005
- Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donorsBlood, 2003
- Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic TransplantsScience, 2002
- HLA class I recognition by killer cell Ig-like receptorsSeminars in Immunology, 2000
- In search of the ‘missing self’: MHC molecules and NK cell recognitionImmunology Today, 1990
- Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategyNature, 1986
- „Natural”︁ killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cellEuropean Journal of Immunology, 1975